The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis
Lennart Lenk(University Hospital Schleswig-Holstein), Denis M. Schewe(Klinik und Poliklinik für Kinder- und Jugendmedizin), Matthias Peipp(Hochschule für Angewandte Wissenschaften Kiel), Judith M. Boer(Princess Máxima Center), Julia Alten(Christian-Albrechts-Universität zu Kiel), Thomas Schüler(Otto-von-Guericke-Universität Magdeburg), Martin Schrappe(University Hospital Schleswig-Holstein), Gabriele Escherich(Universität Hamburg), Frédérique Corallo(OSE Immunotherapeutics (France)), Julien Taurelle(OSE Immunotherapeutics (France)), Anna Laqua(University Hospital Schleswig-Holstein), Monique L. den Boer(Princess Máxima Center), Gunnar Cario, Anna Dietterle(Christian-Albrechts-Universität zu Kiel), Nicolas Poirier(OSE Immunotherapeutics (France)), Julia Heymann(Christian-Albrechts-Universität zu Kiel), Dorothee Winterberg(Christian-Albrechts-Universität zu Kiel), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Vladyslava Dovhan(Otto-von-Guericke-Universität Magdeburg), Stéphanie Neyton(OSE Immunotherapeutics (France)), Irène Baccelli(OSE Immunotherapeutics (France)), Željko Antić(Princess Máxima Center), Monika Brüggemann(University Hospital Schleswig-Holstein), Fotini Vogiatzi(Christian-Albrechts-Universität zu Kiel), Simon Raffel(Heidelberg University), Emma Narbeburu(OSE Immunotherapeutics (France)), Mylène Déramé(OSE Immunotherapeutics (France)), Anke K. Bergmann(Medizinische Hochschule Hannover), Caroline Mary(OSE Immunotherapeutics (France)), Claas Reimer(Christian-Albrechts-Universität zu Kiel), Beat Bornhäuser(University Children's Hospital Zurich), Wiebke Weßels(University Hospital Schleswig-Holstein), Sabrina Pengam(OSE Immunotherapeutics (France))
Cited by 20
Related Papers
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
|Journal of Clinical Oncology|2015|1k
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
|The Lancet|1998|964
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
|The Lancet Oncology|2009|932